Use of pegfilgrastim support on day 9 to maintain relative dose intensity of chemotherapy in breast cancer patients receiving a day 1 and 8 CMF regimen

Clinical and Translational Oncology

Volumn 11, Issue 12, 2009, Pages 842-848

  Casas, Ana ^a   Mattioli, Rodolfo ^b   Gridelli, Cesare ^c   Castellanos, Javier ^d   Duque, Antonio ^e   Falcone, Alfredo ^f   Mansutti, Mauro ^g   Bacon, Pam ^h   Lawrinson, Sue ⁱ   Skacel, Tomas ^h   Belon, J ^j   Estevez L ^j   Mata, J ^j   Scanni, A ^j  

^a HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

^b S CROCE E CARLE HOSPITAL   (Italy)

^c San Giuseppe Moscati   (Italy)

^d Medical Oncology Department   (Spain)

^e HOSPITAL UNIVERSITARIO VIRGEN MACARENA   (Spain)

^f UO di Oncologia   (Italy)

^g Oncology Department   (Italy)

^h AMGEN INC   (United States)

ⁱ AMGEN LTD   (United Kingdom)

^j NONE

more..

Author keywords

Breast cancer; Chemotherapy; Dose delays; Dose reductions; Febrile neutropenia; G CSF; Relative dose intensity

Indexed keywords

CYCLOPHOSPHAMIDE; FLUOROURACIL; METHOTREXATE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;

ABDOMINAL PAIN; ADULT; AGED; ARTHRALGIA; ARTICLE; ASTHENIA; BACKACHE; BLOOD TOXICITY; BONE PAIN; BREAST CANCER; CLINICAL PROTOCOL; CLINICAL TRIAL; CONJUNCTIVITIS; CONSTIPATION; DEEP VEIN THROMBOSIS; DIARRHEA; DRUG EFFICACY; DRUG FEVER; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEBRILE NEUTROPENIA; FEMALE; HUMAN; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; MEDICAL ASSESSMENT; MUCOSA INFLAMMATION; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; MUSCULOSKELETAL PAIN; MYALGIA; NAUSEA; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PHYSICAL EXAMINATION; RHINOPHARYNGITIS; SIDE EFFECT; SINGLE DRUG DOSE; THORAX PAIN; VOMITING;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; BREAST NEOPLASMS, MALE; CARCINOMA; CHEMOTHERAPY, ADJUVANT; CYCLOPHOSPHAMIDE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; FILGRASTIM; FLUOROURACIL; HUMANS; INJECTIONS, INTRAVENOUS; MALE; METHOTREXATE; MIDDLE AGED; NEUTROPENIA; TREATMENT OUTCOME;

EID: 73549113537     PISSN: 1699048X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12094-009-0453-4     Document Type: Article

References (18)

1. D.R. Budman D.A. Berry C.T. Cirrincione, et al. 1998 Dose and dose intensity as determinants of outcome in the adjuvant treatment of breast cancer. The Cancer and Leukemia Group B J Natl Cancer Inst 90 1205 1211 10.1093/jnci/90.16.1205 1:CAS:528:DyaK1cXlslylt7w%3D 9719081
2. R.C. Leonard D. Miles R. Thomas F. Nussey 2003 Impact of neutropenia on delivering planned adjuvant chemotherapy: UK audit of primary breast cancer patients Br J Cancer 89 2062 2068 10.1038/sj.bjc.6601279 1:CAS:528: DC%2BD3sXpt1CitL0%3D 14647139 (Pubitemid 38030904)
3. G. Bonadonna P. Valagussa A. Moliterni, et al. 1995 Adjuvant cyclophosphamide, methotrexate, and fluorouracil in node-positive breast cancer The results of 20yearsoffollow-up.NEnglJMed332 901 906
4. J.R. Mackey J. Cantin J. Chang, et al. 2001 Role of hematopoietic growth factors in the prevention of neutropenic complications for breast cancer patients treated with docetaxel, doxorubicin, and cyclophosphamide (TAC): Results of a randomized double-blind phase III trial -BCIRG 004 Proc Am Soc Clin Oncol 20 10a
5. R. Pettengell H. Gurney J.A. Radford, et al. 1992 Granulocyte colony-stimulating factor to prevent dose-limiting neutropenia in non-Hodgkin's lymphoma: a randomized controlled trial Blood 80 1430 1436 1:STN:280: DyaK38zptlSrtA%3D%3D 1381626
6. V. Trillet-Lenoir J. Green C. Manegold, et al. 1993 Recombinant granulocyte colony stimulating factor reduces the infectious complications of cytotoxic chemotherapy Eur J Cancer 29A 319 324 10.1016/0959-8049(93)90376-Q 1:STN:280:DyaK2c%2FgtFSnsw%3D%3D 7691119
7. N.J. Meropol L.L. Miller E.L. Korn, et al. 1992 Severe myelosuppression resulting from concurrent administration of granulocyte colony-stimulating factor and cytotoxic chemotherapy J Natl Cancer Inst 84 1201 1203 10.1093/jnci/84.15.1201 1:STN:280:DyaK38zktFerug%3D%3D 1378905
8. E.K. Rowinsky L.B. Grochow S.E. Sartorius, et al. 1996 Phase I and pharmacologic study of high doses of the topoisomerase I inhibitor topotecan with granulocyte colony-stimulating factor in patients with solid tumors J Clin Oncol 14 1224 1235 1:CAS:528:DyaK28XisFyktrg%3D 8648378
9. S.P. Ackland A. Anton G.P. Breitbach 2001 Dose-intensive epirubicinbased chemotherapy is superior to an intensive intravenous cyclophosphamide, methotrexate, and fl uorouracil regimen in metastatic breast cancer: a randomized multinational study J Clin Oncol 19 943 953 1:CAS:528: DC%2BD3MXhvFersbo%3D 11181656
10. B.K. Link G.T. Budd S. Scott 2001 Delivering adjuvant chemotherapy to women with early-stage breast carcinoma: current patterns of care Cancer 92 1354 1367 10.1002/1097-0142(20010915)92:6<1354::AID-CNCR1458>3.0.CO;2-P 1:CAS:528:DC%2BD3MXnvVyhu7s%3D 11745211 (Pubitemid 32947818)
11. W.C. Zamboni 2003 Pharmacokinetics of pegfilgrastim Pharmacotherapy 23 9S 14S 10.1592/phco.23.9.9S.32888 1:CAS:528:DC%2BD3sXmsl2rtL4%3D 12921217
12. M.D. Green H. Koelbl J. Baselga 2003 A randomized, double-blind, multicenter phase III study of fixed-dose single-administration pegfilgrastim versus daily filgrastim in patients receiving myelosuppressive chemotherapy Ann Oncol 14 29 35 10.1093/annonc/mdg019 1:STN:280:DC%2BD38jisFektQ%3D%3D 12488289 (Pubitemid 36150255)
13. F.A. Holmes J.A. O'shaughnessy S. Vukelja, et al. 2002 Blinded, randomized, multicenter study to evaluate single administration pegfilgrastim once per cycle versus daily filgrastim as an adjunct to chemotherapy in patients with high-risk stage II or stage III/IV breast cancer J Clin Oncol 20 727 731 10.1200/JCO.20.3.727 1:CAS:528:DC%2BD38XhsVGmt7s%3D 11821454 (Pubitemid 34111380)
14. S. Siena M.J. Piccart F.A. Holmes, et al. 2003 A combined analysis of two pivotal randomized trials of a single dose of pegfilgrastim per chemotherapy cycle and daily filgrastim in patients with stage II-IV breast cancer Onc Rep 10 715 724 1:CAS:528:DC%2BD3sXjsVOltLk%3D
15. T. Wolf J.L. Densmore 2004 Pegfilgrastim use during chemotherapy: current and future applications Curr Hematol Rep 3 419 423 15496275
16. M.S. Aapro D.A. Cameron R. Pettengell, et al. 2006 EORTC guidelines for the use of granulocytecolony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphomas and solid tumours Eur J Cancer 42 2433 2453 10.1016/j.ejca.2006.05.002 1:CAS:528:DC%2BD28XhtVagtrbL 16750358 (Pubitemid 44442936)
17. R. Riedel J. Garst F. Dunphy, et al. 2003 Dosedense carboplatin/ vinorelbine with pegfilgrastim support for the treatment of thoracic malignancies Proc Am Soc Clin Oncol 22 703
18. B.V. Fortner L.S. Schwartzberg J. Ashley, et al. 2003 A single pegfilgrastim dose per cycle maintains neutrophil counts after docetaxel (D) and gemcitabine (Gem) chemotherapy for advanced non-small cell lung cancer Proc Am Soc Clin Oncol 22 696